Resveratrol

Generic Name: Resveratrol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂O_₃

CAS Number: 501-36-0

Unique Ingredient Identifier: Q369O8926L

Background: Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Indication: Being investigated for the treatment of Herpes labialis infections (cold sores).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

Early Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Other: Placebo
Drug: Resveratrol

First Posted Date: 2019-01-28

Last Posted Date: 2024-04-29

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 26

Registration Number: NCT03819517

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

Phase 3

Completed

Conditions: Peripheral Artery Disease

Interventions: Drug: Nicotinamide riboside
Drug: Resveratrol
Other: Placebo

First Posted Date: 2018-11-16

Last Posted Date: 2023-06-26

Lead Sponsor: Northwestern University

Target Recruit Count: 90

Registration Number: NCT03743636

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Multimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER)

Phase 2

Conditions: Gulf War Illness

Interventions: Drug: Resveratrol

First Posted Date: 2018-09-11

Last Posted Date: 2018-09-11

Lead Sponsor: VISN 17 Center of Excellence

Target Recruit Count: 68

Registration Number: NCT03665740

Locations: 🇺🇸
VISN 17 Center of Excellence for Research on Returning War Veterans, Waco, Texas, United States

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure Chronic

Interventions: Drug: Resveratrol
Drug: Placebo

First Posted Date: 2018-05-15

Last Posted Date: 2023-01-12

Lead Sponsor: University of Alberta

Target Recruit Count: 13

Registration Number: NCT03525379

Locations: 🇨🇦
Alberta Cardiovascular and Stroke Research Centre, Edmonton, Alberta, Canada

Resveratrol as a Preventive Treatment of OHSS

Phase 3

Completed

Conditions: Infertility

Interventions: Drug: Resveratrol
Drug: Placebo

First Posted Date: 2018-02-27

Last Posted Date: 2019-08-20

Lead Sponsor: IVI Madrid

Target Recruit Count: 70

Registration Number: NCT03446625

Locations: 🇪🇸
Ivi Madrid, Madrid, Spain

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

Phase 2

Completed

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: Sirolimus
Drug: Resveratrol

First Posted Date: 2017-08-18

Last Posted Date: 2023-02-01

Lead Sponsor: University of Cincinnati

Target Recruit Count: 25

Registration Number: NCT03253913

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Oral Resveratrol to Prevent Post-ERCP Pancreatitis

Phase 4

Conditions: Gastrointestinal Disease
Pancreatitis, Acute

Interventions: Drug: Resveratrol
Drug: Indomethacin

First Posted Date: 2016-10-28

Last Posted Date: 2016-10-28

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 2700

Registration Number: NCT02947932

Resveratrol in Knee Osteoarthritis

Phase 3

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: oral resveratrol
Drug: oral placebo

First Posted Date: 2016-09-19

Last Posted Date: 2024-10-28

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 142

Registration Number: NCT02905799

Locations: 🇫🇷
Rehabilitation department , CHU Clermont-Ferrand, Cebazat, France
🇫🇷
Rheumatology Department, Saint Antoine Hospital, Paris, France
🇫🇷
Rehabilitation Department, Cochin Hospital, Paris, France